Edited by: Cristiano Capurso, University of Foggia, Italy
Reviewed by: Jonathan Cueto-Escobedo, Universidad Veracruzana, Mexico
Pablo Bagnati, Fundación Para la Lucha Contra las Enfermedades Neurológicas de la Infancia (FLENI), Argentina
*Correspondence: Rong Li,
†These authors have contributed equally to this work and share first authorship
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
This study investigates how anxiety, depression, and sleep disorders impact heart rate variability (HRV) in the elderly, exploring the clinical implications of HRV changes.
We examined 355 patients (163 men, 192 women) at Xijing Hospital from July 2021 to December 2022 during health check-ups. Demographics were recorded, and emotional status was assessed using the Hamilton Anxiety Scale (HAMA) and the Hamilton Depression Scale (HAMD). The Pittsburgh Sleep Quality Scale (PSQI) evaluated sleep quality. Patients were categorized into groups A-G based on the presence of emotional states and sleep disorders. HRV indices—SDNN, SDANN, RMSSD, PNN50, LF/HF, LF, and HF—were analyzed using ANOVA and multivariate logistic regression.
No statistically significant differences were observed in demographic, clinical, and lifestyle factors across the eight groups. Variables assessed included age, sex, body mass index (BMI), fasting blood glucose, glycated hemoglobin (HbA1c), blood lipids, blood pressure, heart rate, and histories of smoking and alcohol consumption. Additionally, the presence of hypertension, diabetes, coronary heart disease, marital status, income, and education level were evaluated, with all showing equivalence (
HRV indices of individuals with varying emotional states and sleep disorders exhibited varying degrees of decrease. Anxiety, depression, and sleep disorders presented a superimposed effect on HRV. SDNN, SDANN, RMSSD, PNN50, HF and LF of HRV are of great reference value in the diagnosis of emotional and sleep disorders. For elderly patients experiencing cognitive impairment, HRV is anticipated to serve as a convenient and effective tool for assessing mood and sleep disorders.
The aging population has emerged as a pressing global social issue, as evidenced by the data from China’s seventh population census (
Heart rate variability (HRV) is defined as the variance in time intervals between consecutive heartbeats. It is a collection of parameter values utilized to quantify variations in the R-R interval through various algorithms, serving as a precise indicator of alterations in the autonomic nervous system (
This case-control study involved the continuous collection of information from inpatients and outpatients who underwent mental status and sleep quality evaluations at Xijing Hospital between July 2021 and December 2022. The sample size was determined based on the prevalence of anxiety, depression, and sleep disorders among elderly individuals, with exclusion criteria applied to cases that dropped out during the study or failed to meet data requirements. Ultimately, 313 patients were selected for the study group. Control group samples were primarily drawn from the inpatient and outpatient populations undergoing physical examinations at Xijing Hospital, resulting in a total of 42 participants.
The participants were randomly assessed using the Hamilton Anxiety Scale (HAMA), Hamilton Depression Scale (HAMD), and Pittsburgh Sleep Quality Scale (PSQI) scales by researchers with professional training in psychosomatic medicine to ensure alignment between the participants’ actual psychological and sleep conditions and the scale scores.
All subjects were grouped as follows. Group A: Anxiety group, 45 cases; Group B: Depression group, 42 cases; Group C: Sleep disorder group, 43 cases; Group D: Anxiety combined with depression group, 44 cases; Group E: Anxiety combined with sleep disorder group, 46 cases; Group F: Depression combined with sleep disorder group, 47 cases; Group G: Anxiety, depression and sleep disorder group, 46 cases; Group H: Control group, 42 cases.
Participants with psychological or sleep disorders must meet the following criteria: 1) Age ≥60 years; 2) Meeting the diagnostic criteria of the Chinese Classification of Mental Disorders-3 (CCMD-3) (
Exclusion criteria for the patients include: 1) Patients with a history of atrioventricular block, atrial fibrillation, premature atrial or ventricular arrhythmias; 2) Patients diagnosed with intellectual disability, delirium, schizophrenia, or other mental illnesses according to the CCMD-3; 3) A range of factors that may impact HRV, including hyperthyroidism, anemia, infection, trauma, and other physical ailments; 4) Patients with severe organic diseases such as acute cerebral infarction, malignant tumors, and cachexia; 5) Those who have recently undergone major catastrophic events or experienced significant stress; 6) Individuals experiencing insomnia due to physical discomfort or fatigue; 7) Patients with Parkinson’s syndrome, sleep apnea syndrome; 8) Recent use of anti-anxiety and antidepressant medications; 9) Participants who have recently used medications that impact heart rate, such as beta-blockers, thyroid hormones, and digitalis within the preceding two weeks.
The inclusion criteria for the control group were as follows: 1) Individuals aged 60 years or older; 2) Scoring below 17 on the HAMD and below 17 on the HAMA, as well as below 14 points on the PSQI; 3) Willingness to participate in a 24-hour ECG monitoring; and 4) Possession of complete medical records and signed informed consent.
The exclusion criteria for the control group include: 1) Patients with a history of atrioventricular block, atrial fibrillation, premature atrial or ventricular arrhythmias; 2) Individuals meeting the diagnostic criteria for anxiety and depression according to the CCMD-3; 3) Patients diagnosed with sleep disorders based on the PSQI and subjective reports of frequent and persistent difficulty falling asleep and/or maintaining sleep, as well as dissatisfaction with sleep as determined by clinicians; 4) Individuals with conditions known to affect HRV, such as hyperthyroidism, anemia, and other physical illnesses; 5) Patients with severe organic diseases such as acute cerebral infarction, severe infection and cachexia; 6) Recent major catastrophic events or high stress levels; 7) Parkinson’s syndrome, sleep apnea syndrome, and recent use of anti-anxiety and antidepressant medications.
Demographic data was collected using a standardized questionnaire to ensure the scientific rigor and accuracy of the study, allowing for a comprehensive review of participants’ background information and health status, including age, sex, body mass index, fasting blood glucose, glycated hemoglobin, blood lipids, blood pressure, heart rate, smoking history, drinking history, hypertension history, diabetes history, coronary heart disease history, marital status, income, and education.
All the participants were evaluated their psychological state using the HAMD and the HAMA. Additionally, the PSQI was utilized to assess the sleep quality of the patients. Two trained evaluators from the psychosomatic department conducted joint examinations of the patients and independently scored them, with the average scores being recorded.
The participants underwent 24-hour monitoring using a V12 dynamic ECG recorder. ECG interference signals were eliminated through computer processing, and manual filtering was used to remove artifacts and ectopic beats. The HRV index was computed using an algorithmic system. The recorded data included four time-domain analysis indicators: SDNN, SDANN, RMSSD, PNN50, and three frequency domain analysis indicators: LF, HF, LF/HF (
All participants underwent assessment using the HAMA consisting of 14 items and the HAMD consisting of 17 items. A diagnosis of anxiety disorder was made if HAMA scores were equal to or greater than 14, while a diagnosis of depression disorder was made if HAMD scores were equal to or greater than 17, based on the symptoms reported by the participants over the past three months. Sleep quality was assessed using the PSQI, with scores equal to or greater than 10 indicating a sleep disorder. Higher PSQI scores were indicative of poorer sleep quality.
Normality of the variables was assessed using the Shapiro-Wilk test, and variables conforming to a normal distribution were presented as mean ± standard deviation (
There were no significant differences in age, sex, body mass index, fasting blood glucose, glycated hemoglobin, blood lipid, blood pressure, heart rate, smoking history, drinking history, hypertension history, diabetes history, coronary heart disease history, marital status, income and education among the eight groups (
Comparison of Clinical baseline data across seven patients groups and control group.
| Group A | Group B | Group C | Group D | Group E | Group F | Group G | Group H |
|
|
|---|---|---|---|---|---|---|---|---|---|
| n | 45 | 42 | 43 | 44 | 46 | 47 | 46 | 42 | |
| Famale [n(%)] | 25(55.6) | 22(47.6) | 24(55.8) | 27(61.4) | 20(43.5) | 29(61.7) | 26(56.5) | 19(45.2) | 0.581 |
| Age (year) | 69.7 ± 6.2 | 69.3 ± 8.4 | 70.8 ± 13.0 | 70.7 ± 8.3 | 68.9 ± 8.7 | 72.3 ± 9.6 | 72.7 ± 8.7 | 72.0 ± 8.0 | 0.271 |
| BMI (kg/m2) | 25.2 ± 2.8 | 25.6 ± 3.8 | 24.9 ± 4.3 | 24.3 ± 3.2 | 24.7 ± 3.4 | 24.0 ± 2.9 | 23.9 ± 2.9 | 24.1 ± 3.0 | 0.147 |
| HbA1c (%) | 6.3 ± 1.6 | 5.9 ± 0.9 | 5.6 ± 1.1 | 6.1 ± 1.5 | 6.2 ± 2.2 | 6.5 ± 2.3 | 6.2 ± 1.2 | 6.0 ± 1.1 | 0.262 |
| FBG (mmol/L) | 6.3 ± 2.3 | 5.7 ± 1.3 | 6.0 ± 2.3 | 5.9 ± 1.9 | 5.4 ± 1.4 | 6.2 ± 2.3 | 6.2 ± 2.0 | 5.5 ± 1.3 | 0.095 |
| TC (mmol/L) | 4.2 ± 1.1 | 4.3 ± 1.1 | 4.0 ± 1.3 | 4.3 ± 1.1 | 4.2 ± 1.0 | 3.9 ± 1.0 | 4.1 ± 1.0 | 3.6 ± 1.3 | 0.059 |
| TG (mmol/L) | 1.7 ± 1.0 | 1.7 ± 1.0 | 1.4 ± 1.1 | 1.4 ± 0.9 | 1.6 ± 1.0 | 1.4 ± 0.7 | 1.3 ± 0.6 | 1.2 ± 0.6 | 0.053 |
| HDL (mmol/L) | 1.1 ± 0.3 | 1.1 ± 0.2 | 1.2 ± 0.5 | 1.2 ± 0.4 | 1.2 ± 0.3 | 1.1 ± 0.4 | 1.3 ± 0.4 | 1.2 ± 0.4 | 0.125 |
| LDL (mmol/L) | 2.6 ± 0.9 | 2.6 ± 0.9 | 2.3 ± 1.1 | 2.5 ± 0.9 | 2.5 ± 0.9 | 2.3 ± 0.8 | 2.3 ± 0.9 | 2.0 ± 1.1 | 0.054 |
| SBP (mmHg) | 130 ± 16 | 128 ± 15 | 130 ± 20 | 132 ± 19 | 128 ± 15 | 130 ± 18 | 135 ± 21 | 127 ± 16 | 0.425 |
| DBP (mmHg) | 77 ± 10 | 76 ± 11 | 79 ± 13 | 74 ± 12 | 78 ± 11 | 74 ± 14 | 76 ± 12 | 73 ± 11 | 0.128 |
| HR | 65.9 ± 9.6 | 70.3 ± 10.3 | 69.7 ± 8.7 | 67.3 ± 9.2 | 65.9 ± 9.1 | 66.2 ± 8.8 | 66.7 ± 7.8 | 65.8 ± 9.0 | 0.111 |
| Smoking [n(%)] | 14(31.1) | 16(38.1) | 13(30.2) | 15(34.1) | 18(39.1) | 16(34.0) | 17(37.0) | 15(35.7) | 0.973 |
| Drinking [n(%)] | 13(28.9) | 7(16.7) | 8(18.6) | 9(20.5) | 14(30.4) | 14(29.8) | 12(26.1) | 8(19.0) | 0.719 |
| Hypertension[n(%)] | 29(64.4) | 25(59.5) | 26(60.5) | 31(70.5) | 35(76.1) | 38(80.9) | 36(78.3) | 25(59.5) | 0.074 |
| Diabetes [n(%)] | 9(20.0) | 10(23.8) | 8(18.6) | 11(25.0) | 7(15.2) | 15(31.9) | 13(28.3) | 9(21.4) | 0.623 |
| CHD[n(%)] | 18(40.0) | 19(45.2) | 20(46.5) | 22(50.0) | 17(37.0) | 25(53.2) | 21(45.7) | 19(45.2) | 0.797 |
| Average annual income (ten thousand yuan) | 6.1 ± 2.2 | 6.5 ± 2.7 | 5.2 ± 2.4 | 5.5 ± 2.5 | 5.3 ± 2.5 | 5.4 ± 2.3 | 5.2 ± 2.5 | 6.0 ± 2.5 | 0.114 |
| Married [n(%)] | 43(95.6) | 41(97.6) | 43(100) | 42(95.5) | 43(93.5) | 45(95.7) | 45(97.8) | 39(92.9) | 0.733 |
| Education years | 3.7 ± 2.2 | 3.5 ± 2.3 | 3.3 ± 2.7 | 4.3 ± 2.8 | 4.2 ± 3.1 | 4.5 ± 2.8 | 4.6 ± 2.7 | 4.5 ± 2.8 | 0.135 |
The measurement data in the table is expressed as (
HRV serves as a valuable metric for assessing autonomic nervous system function, particularly in its capacity to reflect the equilibrium between sympathetic and vagal nerve activity. It has been widely used in different areas of research, from basic research to clinical applications to assess health and disease states. Consequently, this study involved a comparative analysis of diverse HRV indices across the eight groups, with the control group exhibiting HRV indices superior to the reference values, whereas the remaining groups demonstrated a decrease in varying degrees relative to the control group. This comparison provides insights into the differential impact on autonomic function as reflected by HRV across different study groups.
Given that this study incorporated the three exposure factors of anxiety, depression, and sleep disorders, it is meaningful to make comparisons between groups with overlapping exposure factors and between groups with exposure factors and normal people. This approach allowed for a more nuanced analysis of how each factor might independently contribute to the observed outcomes. The results showed that there were significant differences in HRV parameters such as SDNN, SDANN, RMSSD, PNN50, LF/HF, LF, HF among different groups. In comparison to Group A and Group B, the HRV parameters of Group D exhibited a decrease; in comparison to Group A and Group C, the HRV parameters of Group E, with the exception of LF/HF and HF, also showed a decrease; in comparison to Group B and Group C, all HRV parameters of Group F displayed a decrease. Group G demonstrated a significant decrease in HRV parameters, excluding LF/HF, when compared to the other groups, while Group H showed an increase in HRV parameters, excluding LF/HF, with a statistically significant difference (
Individuals with sleep disorders often utilize sedatives and hypnotics, including medications like diazepam, eszopiclone, and zolpidem tartrate; thus, it is not feasible to entirely exclude participants using these drugs. Acknowledging the potential influence of sedatives and hypnotics on HRV outcomes, this study compared HRV indicators between groups that included individuals on sedatives and hypnotics (C, E, F, and G) and those who had never used such medications (C*, E*, F*, and G*). Furthermore, the trend in HRV changes was consistent across the relevant groups. Refer to
Comparison of HRV among seven patients groups and control group.
| Groups/Values | n | SDNN | SDANN | RMSSD | PNN50(%) | LF/HF | LF | HF |
|---|---|---|---|---|---|---|---|---|
| Group A | 45 | 112.98 ± 29.22#^~△☆□ | 97.71 ± 22.88#^~△☆□ | 55.47 ± 46.18#^~△☆□ | 23.26 ± 23.43#^~△☆□ | 2.66 ± 1.23# | 395.17 ± 261.16#^~△☆□ | 165.72 ± 109.78#~△□ |
| Group B | 42 | 117.79 ± 31.50#&~△◇□ | 109.21 ± 25.48#&~△◇□ | 47.62 ± 51.28#&~△◇□ | 14.67 ± 16.96#&~△◇□ | 1.11 ± 0.72#&◇ | 353.41 ± 158.76#&~△◇□ | 459.04 ± 418.56#&~△◇□ |
| Group C | 43 | 127.19 ± 25.25^&~△ | 114.19 ± 34.46^&~△ | 59.21 ± 45.65^&~△ | 33.14 ± 21.83^&~△ | 1.10 ± 0.52& | 746.79 ± 262.27^&~△ | 779.50 ± 346.13&~△ |
| Group D | 44 | 92.75 ± 17.54~△□ | 81.70 ± 24.33~△□ | 22.30 ± 8.48~△□ | 5.04 ± 9.67~△□ | 1.11 ± 0.66 | 131.82 ± 90.28~△□ | 134.52 ± 76.75~△□ |
| Group E | 46 | 107.00 ± 19.08~△ | 97.46 ± 27.16~△ | 28.13 ± 13.16~△ | 5.07 ± 4.17~△ | 2.18 ± 3.13 | 331.30 ± 193.51~△ | 232.43 ± 142.03~△ |
| Group F | 47 | 100.09 ± 28.24~△ | 92.64 ± 40.02~△ | 41.36 ± 24.70~△ | 9.61 ± 7.71~△ | 0.65 ± 0.70 | 126.03 ± 62.35~△ | 284.85 ± 157.36~△ |
| Group G | 46 | 82.93 ± 29.70△ | 71.43 ± 26.69△ | 17.28 ± 6.58△ | 1.42 ± 1.95△ | 1.07 ± 0.59 | 73.61 ± 75.49△ | 80.99 ± 76.53△ |
| Group H | 42 | 183.38 ± 55.04~□ | 134.98 ± 47.81~□ | 198.02 ± 92.46~□ | 53.66 ± 26.72~□ | 0.61 ± 0.47 | 7502.09 ± 7246.60~□ | 16562.93 ± 16328.04~□ |
| Group C* | 11 | 137.45 ± 21.02☆◇□△ | 130.64 ± 35.34☆◇□△ | 89.91 ± 43.295☆◇□△ | 44.88 ± 19.37☆◇□△ | 1.03 ± 0.43◇ | 887.87 ± 202.81☆◇□△ | 959.94 ± 335.05◇□△ |
| Group E* | 11 | 88.45 ± 14.75 □△ | 71.73 ± 31.55□△ | 30.36 ± 19.13□△ | 4.32 ± 4.47□△ | 1.70 ± 0.80 | 294.76 ± 140.80□△ | 154.39 ± 76.75□△ |
| Group F* | 10 | 75.70 ± 13.26 □△ | 67.00 ± 13.65□△ | 32.20 ± 12.35□△ | 7.25 ± 7.71□△ | 0.94 ± 1.19 | 130.19 ± 62.92□△ | 292.76 ± 237.49□△ |
| Group G* | 7 | 48.86 ± 9.51△ | 38.00 ± 5.32△ | 15.29 ± 5.31△ | 1.55 ± 2.02△ | 1.06 ± 0.81 | 41.86 ± 20.17△ | 61.41 ± 45.54△ |
| P value | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 | |
| F value | 42.25 | 16.47 | 73.90 | 51.20 | 13.55 | 44.31 | 44.42 | |
| P* |
<0.01 | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 | <0.01 | |
| F* value | 35.48 | 43.96 | 19.11 | 28.19 | 22.82 | 23.60 | 23.80 |
SDNN, standard deviation of normal to normal intervals; SDANN, the standard deviation of the averages of 5-minute RR intervals; RMSSD, root mean square of successive RR interval differences; PNN50, percentage of successive RR intervals that differ by more than 50 ms; LF, low frequency; HF, high frequency. *:Groups or values analysed among people without taking sedative or hypnotic drugs. #P<0.01 versus D; ^P<0.01 versus E; &P<0.01 versus F; ~P<0.01 versus G; △P<0.01 versus H; ☆P<0.01 versus E*; ◇P<0.01 versus F*; □P<0.01 versus G*.
This study focused on a cohort of patients diagnosed with anxiety, depression, and sleep disorders to investigate the potential influence of these prevalent mood disorders on HRV. Multivariate logistic regression analysis was employed to examine the association between anxiety, depression, and sleep disorders with various indicators of HRV, including SDNN, SDANN, RMSSD, PNN50, LF, HF, and LF/HF, as dependent variables. The presence of anxiety, depression, and sleep disorders were considered as independent variables in the model. Various confounding factors, including BMI, smoking history, drinking history, hypertension, diabetes, and coronary heart disease, were controlled for in the study of patients with anxiety, depression, and sleep disorders. Regression analysis revealed a significant association between anxiety and multiple HRV indicators. Specifically, anxiety was identified as an independent risk factor for reduced SDNN, SDANN, and LF (
Logistic regression analysis was used to analyze the effect of anxiety patients on HRV.
| HRV parameters |
|
Wald χ2 |
|
|
|
|---|---|---|---|---|---|
| SDNN(ms) | 1.253 | 6.443 | 0.01 | 3.50 | 1.33∼9.03 |
| SDANN(ms) | 1.255 | 6.836 | 0.01 | 3.51 | 1.37∼8.99 |
| LF/HF | -3.717 | 34.922 | <0.01 | 0.24 | 0.01∼0.08 |
| LF(Hz) | 2.779 | 17.136 | <0.01 | 16.10 | 4.32∼60.01 |
The study investigated the impact of depression on HRV by examining indicators such as SDNN, RMSSD, PNN50, and HF as dependent variables, with anxiety, depression, and sleep disorders as independent variables. Multivariate logistic regression analysis revealed that depression was identified as an independent risk factor for the decrease in SDNN, RMSSD, PNN50, and HF (
Logistic regression analysis was used to analyze the effect of depression patients on HRV.
| HRV parameters |
|
Wald χ2 |
|
|
|
|---|---|---|---|---|---|
| SDNN(ms) | 1.19 | 5.63 | 0.02 | 3.28 | 1.23∼8.76 |
| RMMSD(ms) | 2.06 | 17.60 | <0.01 | 7.81 | 2.99∼20.39 |
| PNN50(ms) | 3.64 | 31.87 | <0.01 | 38.00 | 10.75∼134.36 |
| HF(Hz) | 2.33 | 11.99 | <0.01 | 10.92 | 2.75∼38.51 |
In a manner akin to the research methodologies employed in studies on anxiety and depression, the present study designated the decrease in HRV index as the dependent variable, with the presence of anxiety, depression, and sleep disorder serving as the independent variables. Following logistic regression analysis, it was determined that sleep disorder emerged as a significant independent risk factor for the reduction of PNN50 and SDANN (
Logistic regression analysis was used to analyze the effect of patients with sleep disorders on HRV.
| HRV parameters |
|
Wald χ2 |
|
|
|
|---|---|---|---|---|---|
| PNN50(ms) | 1.25 | 6.69 | <0.01 | 3.48 | 1.35∼8.95 |
| SDANN(ms) | 1.72 | 12.45 | <0.01 | 5.61 | 2.15∼14.61 |
HRV serves as a comprehensive measure of the regulation of the cardiac autonomic nervous system, encompassing frequency domain, time domain, and nonlinear indices. Frequency domain indicators such as LF、HF、LF/HF, time domain indicators such as SDNN、SDANN、RMSSD、PNN50, and non-linear indicators such as Poincare map and sample entropy are utilized to assess the complexity and non-linear characteristics of HRV. It is widely accepted among scholars that SDNN primarily signifies the overall activity of the autonomic nerve system. SDANN and LF are indicative of sympathetic nerve activity, with their values decreasing as sympathetic nerve tension increases. RMSSD、PNN50 and HF, on the other hand, reflects vagal nerve activity, with its value decreasing as vagal nerve tension reduces. The LF/HF ratio serves as a quantitative measure for assessing the functional equilibrium of the sympathetic and vagus nerves. The interpretation of HRV indices remains inconclusive. A study suggests that while LF is modulated by sympathetic nerve function, it is not advisable to rely solely on LF to gauge sympathetic nervous system activity, as it is also impacted significantly by vagus nerve activity and other factors. LF/HF can offer insights into the regulatory function of the autonomic nervous system, however, its accuracy is compromised by nonlinear relationships and various influencing factors (
In this research, the elderly population was categorized into groups based on varying emotional states and sleep patterns to analyze discrepancies in HRV indicators among the eight groups. Findings revealed that individuals combined with anxiety, depression, and sleep disorders exhibited a decrease in all HRV metrics, with the exception of LF/HF, compared to the normal control group, with the most pronounced decrease observed in this cohort. Specifically, individuals with comorbid mood and sleep disturbances experienced a more substantial decline in HRV compared to those with singular anxiety, depression, or sleep disorders. This suggests that anxiety, depression, and sleep disorders may contribute to a reduction in HRV and exhibit a synergistic effect, a phenomenon not previously explored in existing literature. Consequently, our findings propose a novel hypothesis: a pronounced decrease in HRV may correlate with heightened emotional instability in patients and poorer sleep quality (
Recent research has increasingly demonstrated the impact of mood disorders, such as anxiety and depression, on HRV (
To sum up, the assessment of emotional disorders in the elderly population is significantly influenced by subjective factors inherent in the scales used (
Previous research has predominantly focused on examining the impact of various physiological and psychological factors on HRV. However, the prevalence of sleep disorders among the elderly poses a significant challenge to their overall physical and mental well-being, yet the potential influence of sleep disorders on HRV in this population remains largely unexplored. It is important to note that not only physical ailments, but also mental health conditions such as anxiety and depression, can contribute to the development of sleep disorders (
The limitation of this study is the lack of a clearly defined normal threshold for various HRV parameters in healthy individuals, despite the observed decrease in these parameters in individuals with anxiety, depression, and sleep disorders, particularly when all three conditions are present simultaneously. Future extensive clinical investigations are anticipated to establish a threshold level for HRV in the elderly demographic, thereby positioning HRV as a primary objective measure for assessing emotions.
Overall, HRV is anticipated to serve as a non-invasive and readily accessible assessment tool for physicians to identify patients potentially affected by negative mood and sleep disorders (
In the diagnosis of emotional disorders, time-domain metrics such as SDNN, SDANN, RMSSD, and PNN50, alongside frequency-domain metrics like HF and LF, hold significant reference value. For diagnosing sleep disorders, the time-domain indicators SDANN and PNN50 of HRV are particularly valuable. Among the elderly with cognitive dysfunction, the application of traditional scales is limited; however, the reduction in related indicators of HRV shows promising clinical potential for aiding in the diagnosis of anxiety, depression, and sleep disorders.
The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.
The studies involving humans were approved by Xijing Hospital Ethics Committee. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.
WL: Conceptualization, Data curation, Formal analysis, Writing – original draft, Writing – review & editing. SW: Data curation, Formal analysis, Methodology, Writing – original draft, Writing – review & editing. HG: Data curation, Writing – original draft, Writing – review & editing. RL: Conceptualization, Formal analysis, Supervision, Writing – original draft, Writing – review & editing.
The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This research was supported by the following grants: National Natural Science Foundation of China (No. 82070263), and Air Force Medical University Clinical Research Program (2022LC2252) and the Shaanxi Key Core Technology Project (2024SF-GJHX-34).
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.